411 related articles for article (PubMed ID: 36674902)
1. Notch Partners in the Long Journey of T-ALL Pathogenesis.
Toribio ML; González-García S
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674902
[TBL] [Abstract][Full Text] [Related]
2. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
[TBL] [Abstract][Full Text] [Related]
3. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
5. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
6. The role of NOTCH1 signaling in T-ALL.
Ferrando AA
Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
[TBL] [Abstract][Full Text] [Related]
7. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
8. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Sanchez-Martin M; Ferrando A
Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
11. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
Kaushik B; Pal D; Saha S
Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
[TBL] [Abstract][Full Text] [Related]
12. An activating intragenic deletion in NOTCH1 in human T-ALL.
Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
[TBL] [Abstract][Full Text] [Related]
13. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
14. Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
Goldshtein A; Berger M
Crit Rev Oncog; 2014; 19(5):399-404. PubMed ID: 25404153
[TBL] [Abstract][Full Text] [Related]
15. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
16. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
17. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL.
Jeannet R; Mastio J; Macias-Garcia A; Oravecz A; Ashworth T; Geimer Le Lay AS; Jost B; Le Gras S; Ghysdael J; Gridley T; Honjo T; Radtke F; Aster JC; Chan S; Kastner P
Blood; 2010 Dec; 116(25):5443-54. PubMed ID: 20829372
[TBL] [Abstract][Full Text] [Related]
19. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
[TBL] [Abstract][Full Text] [Related]
20. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
